#starlightmayhem #oncommand #horror #mayhemofmadnessbelow
#OnC

Tyrese version of Briant if Briant was a monster

(Inspired by @tyresethelad.bsky.social.)

Le #Niger et le #Maroc ont signé une convention pour déployer le #HMS+ au Niger, un système de suivi des #médias visant à renforcer la #régulation et lutter contre la #désinformation. Échanges d'expertise et #formation au programme entre la #HACA du Maroc et l' #ONC du Niger.

#starlightmayhem #oncommand #horror #mayhemofmadnessbelow
#OnC

Helpless!Spine!Briant.

(Redesigned.)

John 11 26 ✝️ ❤️

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC
sptdemo.com/cures-act

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership BeOne Medicines (NASDAQ: ONC) reported Q4 2025 total revenue $1.498B and FY2025 $5.343B, up 33% and 40% year-over-year. Global BRUKINSA revenue was $1.1B Q4 and $3.9B FY, up 38% and 49%. GAAP diluted EPS was $0.58 ADS Q4 and $2.53 ADS FY; non-GAAP diluted EPS was $1.95 ADS Q4 and $8.09 ADS FY. The company provided FY2026 revenue guidance of $6.2–$6.4B and GAAP operating income guidance of $700–$800M.

#ONC BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

www.stocktitan.net/news/ONC/be-one-medicine...

#AMZN #GOOGL #GOOG #ONC #a755235e-6f68-4f7c-af54-87fa90dc4107 #investing #Consumer #Goods

Origin | Interest | Match

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC

https://bit.ly/3Vl8rIp

Johnny is as shocked as he should be in discovering his new housemate is an alien.

#ONC #novella #20kin12wEH #opennovellacontest2026 #EstherTheAuthor #MyWritingMonth #OpenNovellaContest #authorsoftheinternet #girlinthewritinghat #TheWriMoBlog #Wattpad #WattpadWriter
2/2

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC
sptdemo.com/cures-act

Memory Letters cover

New year. New #ONC. New story!

www.wattpad.com/story/407443...

#writingcommunity #opennovellacontest

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC

https://bit.ly/3Vl8rIp

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC
sptdemo.com/cures-act

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA BeOne Medicines (NASDAQ:ONC) reported Phase 3 HERIZON-GEA-01 results showing ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), met the dual primary endpoint of PFS and showed strong survival signals.The ZIIHERA+TEVIMBRA+chemo arm showed mOS 26.4 months (HR=0.72; P=0.0043), a 28% reduction in risk of death and >7-month mOS improvement; both experimental arms achieved mPFS 12.4 months vs 8.1 months control. ORR was ~70% and median DOR reached 20.7 months with the triple regimen. Safety was consistent with known class effects; Grade ≥3 TRAEs were 71.8% (triple arm).BeOne plans regulatory submissions for TEVIMBRA and ZIIHERA based on these data.

#ONC ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

www.stocktitan.net/news/ONC/ziihera-plus-te...

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC

https://bit.ly/3Vl8rIp

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma BeOne Medicines (NASDAQ: ONC) announced that on December 18, 2025 the U.S. FDA granted Fast Track Designation for BGB-B2033, a bispecific antibody targeting GPC3 and 4-1BB for treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression after prior systemic therapy. The designation highlights the program's potential in an area of high unmet need.BeOne is conducting a global, multi-center Phase 1 trial (NCT06427941) to evaluate safety and anti-tumor activity of BGB-B2033 as monotherapy and in combination with PD-1 inhibitor TEVIMBRA (tislelizumab).

#ONC BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

www.stocktitan.net/news/ONC/be-one-medicine...

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC
sptdemo.com/cures-act

Hey Odd Nations, Support your fucking English VA's. #DisventureCamp #ONC #OddNationCartoons

(youtu.be/ebS_XTURQqU?...)

#ONC BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

www.stocktitan.net/news/ONC/brukinsa-delive...

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies BeOne Medicines Ltd., a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology Annual Meeting& Exposition in Orlando,...

#ONC Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

www.stocktitan.net/news/ONC/sonrotoclax-dat...

2/3 L’ONC prévoit une réorganisation interne, l’assainissement du paysage médiatique et un accompagnement renforcé des organes de presse, publics, privés ou en ligne. L’objectif : un espace médiatique « sûr et crédible ». #Médias #Journalisme #Niger #Presse #ONC

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC

https://bit.ly/3Vl8rIp

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines (Nasdaq: ONC) announced the U.S. FDA has accepted and granted Priority Review to the NDA for sonrotoclax, a next‑generation BCL2 inhibitor for adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after prior BTK inhibitor therapy.The NDA is supported by a global Phase 1/2 single‑arm study of 125 patients that met its primary endpoint of overall response rate (IRC‑assessed) and showed promising CR, DOR, and PFS results with a manageable safety profile. Full data will be presented at ASH 2025 (oral, Dec 7).BeOne plans Project Orbis participation and submissions to other regulators including EMA and China NMPA.

#ONC U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

www.stocktitan.net/news/ONC/u-s-fda-grants-...

youtube.com/watch?v=H6qA...

#disventurecamp #oddnationscartoons #onc #DC4 #TDI

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 BeOne Medicines (NASDAQ:ONC) will present nearly 50 abstracts at ASH 2025 (Dec 6-9), including six orals across three hematology programs: BTK inhibitor BRUKINSA (zanubrutinib), BCL2 inhibitor sonrotoclax, and BTK degrader BGB-16673. Key disclosed metrics: SEQUOIA reports an estimated 74% PFS at 6 years in treatment‑naïve CLL/SLL and sustained overall survival of 84% (88% after COVID adjustment); ALPINE long‑term extension reports up to 6 years follow‑up. New sonrotoclax and BGB-16673 data include rapid, deep responses, uMRD findings, and multi‑malignancy activity.

#ONC BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

www.stocktitan.net/news/ONC/be-one-medicine...

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC
sptdemo.com/cures-act

#ONC BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/ONC/be-one-medicine...

Niger : Décret portant nomination des membres de l’Observatoire National de la Communication (ONC).

Sont nommés comme membres de l’ONC :
- Dr Salifou Boubé
- Mme Marie Ambouka
- M. Abdourahamane Varino
- Dr Diallo Amadou Bounty

#Niger #Médias #Presse #Journaliste #ONC

What does full Cures Act compliance mean for your care team? Access, innovation, and trust — all secured. #CuresAct #Compliance #ONC

https://bit.ly/3Vl8rIp